Efficacy and safety of opicinumab in participants with relapsing multiple sclerosis: a randomized, placebo-controlled, Phase 2 trial (AFFINITY Part 1)

被引：0

作者：

Calabresi, P. A. ^{[1
]}

Giovannoni, G. ^{[2
]}

Hartung, H. -P. ^{[3
,4
,5
]}

Naismith, R. T. ^{[6
]}

Fox, R. ^{[7
]}

Sormani, M. -P. ^{[8
]}

Arnold, D. L. ^{[9
,10
]}

Valis, M. ^{[11
]}

Newsome, S. D. ^{[1
]}

Bartholome, E. ^{[12
]}

Belkin, M. I. ^{[13
]}

Cheng, W. ^{[14
]}

Ke, J. ^{[14
]}

Riester, K. ^{[14
]}

Javor, A. ^{[14
]}

Lyons, J. ^{[14
]}

Bradley, D. P. ^{[14
]}

Fisher, E. ^{[14
]}

Naylor, M. L. ^{[14
]}

Belachew, S. ^{[14
]}

Deykin, A. ^{[14
]}

Franchimont, N. ^{[14
]}

Zhu, B. ^{[14
]}

机构：

[1] Johns Hopkins Univ, Div Neuroimmunol & Neuroinfect Dis, Baltimore, MD USA

[2] Barts & London Queen Marys Sch Med & Dent, London, England

[3] Heinrich Heine Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany

[4] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[5] Med Univ Vienna, Dept Neurol, Vienna, Austria

[6] Washington Univ, Ctr Adv Med, Neurosci Ctr, St Louis, MO 63110 USA

[7] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44106 USA

[8] Univ Genoa, Dept Hlth Sci, Genoa, Italy

[9] McGill Univ, Dept Neurol, Montreal, PQ, Canada

[10] NeuroRx Res, Montreal, PQ, Canada

[11] Charles Univ Prague, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic

[12] CHU Tivoli, La Louviere, Belgium

[13] Michigan Inst Neurol Disorders, Farmington Hills, MI USA

[14] Biogen, Cambridge, MA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

147

引用

页码：90 / 91

页数：2

共 50 条

[1] Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
Cadavid, Diego
Mellion, Michelle
Hupperts, Raymond
Edwards, Keith R.
Calabresi, Peter A.
Drulovic, Plena
Giovannoni, Gavin
Hartung, Hans-Peter
Arnold, Douglas L.
Fisher, Elizabeth
Rudick, Richard
Mi, Sha
Choi, Yi
Li, Jie
Zhang, Yiwei
Cheng, Wenting
Xu, Lei
Zhu, Bing
Green, Susan M.
Chang, Ih
Deykin, Aaron
Sheikh, Sarah, I
LANCET NEUROLOGY, 2019, 18 (09): : 845 - 856
[2] A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Polman, CH
O'Connor, PW
Havrdova, E
Hutchinson, M
Kappos, L
Miller, DH
Phillips, JT
Lublin, FD
Giovannoni, G
Wajgt, A
Toal, M
Lynn, F
Panzara, MA
Sandrock, AW
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09): : 899 - 910
[3] Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Kappos, Ludwig
Arnold, Douglas L.
Bar-Or, Amit
Camm, John
Derfuss, Tobias
Kieseier, Bernd C.
Sprenger, Till
Greenough, Kristin
Ni, Pingping
Harada, Tomohiko
LANCET NEUROLOGY, 2016, 15 (11): : 1148 - 1159
[4] Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
Cadavid, Diego
Balcer, Laura
Galetta, Steven
Aktas, Orhan
Ziemssen, Tjalf
Vanopdenbosch, Ludo
Frederiksen, Jette
Skeen, Mark
Jaffe, Glenn J.
Butzkueven, Helmut
Ziemssen, Focke
Massacesi, Luca
Chai, Yi
Xu, Lei
Freeman, Stefanie
LANCET NEUROLOGY, 2017, 16 (03): : 189 - 199
[5] Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Yin, Ming
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
Hauser, Stephen
NEUROLOGY, 2011, 76 (09) : A545 - A545
[6] Safety and tolerability of opicinumab in relapsing multiple sclerosis: the Phase 2b SYNERGY trial
Freeman, S.
Selmaj, K.
Fernandez, O.
Grimaldi, L.
Silber, E.
Pardo, G.
Freedman, S. M.
Zhang, Y.
Xu, L.
Mellion, M.
Cadavid, D.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 323 - 324
[7] Safety and Tolerability of Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial
McCroskery, Peter
Selmaj, Krzysztof
Fernandez, Oscar
Grimaldi, Luigi M. E.
Silber, Eli
Pardo, Gabriel
Freedman, S. Mitchell
Zhang, Yiwei
Xu, Lei
Cadavid, Diego
Mellion, Michelle
NEUROLOGY, 2017, 88
[8] Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis
Spiera, Robert
Hummers, Laura
Chung, Lorinda
Frech, Tracy M.
Domsic, Robyn
Hsu, Vivien
Furst, Daniel E.
Gordon, Jessica
Mayes, Maureen
Simms, Robert
Lafyatis, Robert
Martyanov, Viktor
Wood, Tammara
Whitfield, Michael L.
Constantine, Scott
Lee, Elizabeth
Dgetluck, Nancy
White, Barbara
ARTHRITIS & RHEUMATOLOGY, 2020, 72 (08) : 1350 - 1360
[9] Efficacy and safety of ozanimod from the 2-year blinded extension of RADIANCE: a randomized, double-blind, placebo-controlled Phase 2 trial in relapsing multiple sclerosis
Cohen, J. A.
Selmaj, K.
Arnold, D. L.
Comi, G.
Bar-Or, A.
Olson, A.
Kopicko, J.
Cravets, M.
Frohna, P.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 595 - 596
[10] Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Cohen, Jeffrey A.
Arnold, Douglas L.
Comi, Giancarlo
Bar-Or, Amit
Gujrathi, Sheila
Hartung, Jeffrey P.
Cravets, Matt
Olson, Allan
Frohna, Paul A.
Selmaj, Krzysztof W.
LANCET NEUROLOGY, 2016, 15 (04): : 373 - 381

← 1 2 3 4 5 →